Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07043270 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv5
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 1, 2025 to Sep 29, 2025
    • Site details revised
    v4
  3. Start date: Jul 1, 2025 to Sep 1, 2025v3
  4. Secondary endpoints revised (9)v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this research is to study the effects and safety of alternating neoadjuvant chemotherapy on borderline resectable pancreatic cancer.
Trial Details
NCT Number NCT07043270
Lead Sponsor Dartmouth-Hitchcock Medical Center
Conditions
(from sponsor)		 Pancreas Adenocarcinoma
Related terms Pancreatic Neoplasms
Enrollment 35 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov